Search | Clinical Trials Finder

Conditions: Malignancies Multiple
Interventions: BMS-986205, Itraconazole, Rifampin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Austin, Texas

Conditions: HIV Infections
Interventions: Stavudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Months to 6 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 51
States / cities: Long Beach, California • Los Angeles, California • Oakland, California + 37 more

Conditions: Chronic Hepatitis B
Interventions: Entecavir; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 31
States / cities: Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 28 more

Conditions: Chronic Myeloid Leukemia
Interventions: Not listed
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,494 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 143
States / cities: Muscle Shoals, Alabama • Phoenix, Arizona • Sedona, Arizona + 129 more

Conditions: Stage III (Unresectable) or Stage IV Advanced Melanoma
Interventions: Nivolumab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Timeline: 2014 – 2018
U.S. locations: 23
States / cities: Mobile, Alabama • Encinitas, California • Washington D.C., District of Columbia + 19 more

Conditions: HIV Infections
Interventions: Zidovudine, Zalcitabine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 654 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1993
U.S. locations: 35
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 22 more

Conditions: Carcinoma, Hepatocellular
Interventions: Relatlimab, Nivolumab, Bevacizumab, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 10
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 5 more

Conditions: Hepatitis C
Interventions: DCV/ASV/BMS-791325, DCV/ASV/BMS-791325 + RBV; Drug
Lead sponsor: Timothy Morgan, MD; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Stage IV or Recurrent Non-Small Cell Lung Cancer
Interventions: Nivolumab, Gemcitabine, Cisplatin, Carboplatin, Paclitaxel, Pemetrexed; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 541 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 36
States / cities: Mobile, Alabama • Gilbert, Arizona • Tucson, Arizona + 30 more

Conditions: Lung Adenocarcinoma
Interventions: erlotinib with cetuximab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Conditions: Juvenile Psoriatic Arthritis
Interventions: Deucravacitinib, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 7
States / cities: Lancaster, California • Chicago, Illinois • Indianapolis, Indiana + 4 more

Conditions: Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)
Interventions: Not listed
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 38,396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Lawrenceville, New Jersey

Conditions: HIV Infections
Interventions: Stavudine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 1999
U.S. locations: 3
States / cities: San Diego, California • Portsmouth, Virginia • Seattle, Washington

Conditions: Schizophrenia
Interventions: Xanomeline and Trospium Chloride Capsules; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: Atlanta, Georgia • Louisville, Kentucky • Columbus, Ohio + 2 more

Conditions: Chronic Lymphocytic Leukemia (CLL), Relapsed, Refractory
Interventions: EGFRt/19-28z/4-1BBL CAR T cells; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Urothelial Cancer
Interventions: Nivolumab, Ipilimumab, Gemcitabine, Cisplatin, Carboplatin; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 29
States / cities: Anchorage, Alaska • Fresno, California • Santa Rosa, California + 24 more

Conditions: Rheumatoid Arthritis
Interventions: Double-blind Abatacept, Double-blind Placebo, Open-label Abatacept; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,795 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 44
States / cities: Decatur, Alabama • Paradise, Arizona • Phoenix, Arizona + 41 more

Conditions: Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma
Interventions: Nivolumab, Everolimus; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 821 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 39
States / cities: Fayetteville, Arkansas • La Jolla, California • Los Angeles, California + 29 more

Conditions: Smoldering Plasma Cell Myeloma
Interventions: Dexamethasone, Iberdomide Hydrochloride, Quality-of-Life Assessment; Drug · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Type 2 Diabetes
Interventions: Saxagliptin, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 11
States / cities: Concord, California • Sacramento, California • Denver, Colorado + 8 more

Conditions: Solid Tumors
Interventions: Production of Genetically-modified T cells, Cyclophosphamide, IP Catheter Insertion, Infusion of 4H11-28z/fIL-12/EGFRt+ Genetically-modified T cells, Fludarabine; Procedure · Drug · Device + 1 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: Atazanavir+Ritonavir+Tenofovir, Atazanavir+Ritonavir+Tenofovir+Famotidine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Hamilton, New Jersey

Conditions: Diabetes
Interventions: Insulin, glucose and staple isotopes; Procedure
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Hepatitis C
Interventions: 200 mg INX-08189 Fasted, Placebo QD Fasted, 100 mg INX-08189 QD, Placebo QD, 100 mg INX-08189 with low-fat meal, Placebo with low-fat meal, 100 mg INX-08189 BID Fasted, Placebo BID Fasted, ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy Subjects

A Randomized, Comparative Trial of Zidovudine (AZT) Versus 2',3'-Didehydro-3'-Deoxythymidine (Stavudine; d4T) in Children With HIV Infection

A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Negative for Hepatitis B e Antigen

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Expanded Access Program With Nivolumab to Treat Melanoma

A Comparison of Three Treatments for Advanced HIV Disease in Patients Who Have Received Nucleoside Therapy in the Past

A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer

Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus

An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib

A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis

A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database

A Pilot Study to Compare the Antiviral and Immunologic Effects of Stavudine ( d4T ) Versus Placebo in Subjects With Evidence of Recent HIV Infection.

An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia

A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies

Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer

A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis

Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)

Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma

Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment

Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors

Drug Interaction Study With Famotidine, Atazanavir, and Atazanavir/Ritonavir/Tenofovir

Experimental Study to Validate the Modified Glucose Disposal Test

Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve Subjects